{"DataElement":{"publicId":"2984062","version":"1","preferredName":"Disease or Disorder Fanconi Anemia Status Type","preferredDefinition":"A description of the Fanconi anemia disease or disorder status.","longName":"2512861v1.0:2984055v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2512861","version":"1","preferredName":"Disease or Disorder Status","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time.","longName":"2404658v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B898979-184A-3A90-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-21","endDate":null,"createdBy":"UMLLOADER_AGNIS","dateCreated":"2006-08-21","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2984055","version":"1","preferredName":"Fanconi Anemia Status Type","preferredDefinition":"Fanconi anemia (FA) is an autosomal recessive genetic disorder characterised clinically by progressive bone marrow failure, skeletal deformities and a predisposition to neoplasia. Patient cells manifest an extreme chromosomal instability and hypersensitivity to polyfunctional alkylating agents. It is assumed that the basic defect is related to the repair of DNA damage, in particular that of so-called DNA crosslinks. Currently there are eight complementation groups in FA (FA-A-FA-H) which indicates that at least eight independent genes can lead to FA. Three of these genes have been identified: FANCA, FANCC and FANCG. (from PMID 10472548)_A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2984055v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stable cytopenia with cytogenetic abnormalities (no MDS)","valueDescription":"Stable With Cytogenetic Abnormality Cytopenia","ValueMeaning":{"publicId":"2984056","version":"1","preferredName":"Stable With Cytogenetic Abnormality Cytopenia","longName":"2984056","preferredDefinition":"Stable; subject to little fluctuation; showing little if any change.: Used to indicate the presence of something or someone.: An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.: A reduction in the number of blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable","conceptCode":"C30103","definition":"Subject to little fluctuation; showing little if any change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytopenia","conceptCode":"C2979","definition":"A laboratory test result indicating an abnormally low quantity of circulating blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-7050-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-7069-0231-E040-BB89AD435A9D","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Progressive cytopenia","valueDescription":"Progressive Cytopenia","ValueMeaning":{"publicId":"2984058","version":"1","preferredName":"Progressive Cytopenia","longName":"2984058","preferredDefinition":"Advancing in extent or severity.: A reduction in the number of blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive","conceptCode":"C25254","definition":"Advancing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytopenia","conceptCode":"C2979","definition":"A laboratory test result indicating an abnormally low quantity of circulating blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-709E-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-70B7-0231-E040-BB89AD435A9D","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Myelodysplasia","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2570433","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"2570433","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E02E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-70CB-0231-E040-BB89AD435A9D","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Leukemia, untreated","valueDescription":"Without Therapy Leukemia","ValueMeaning":{"publicId":"2984059","version":"1","preferredName":"Without Therapy Leukemia","longName":"2984059","preferredDefinition":"Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-70D9-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-70F2-0231-E040-BB89AD435A9D","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Leukemia, treated","valueDescription":"With Therapy Leukemia","ValueMeaning":{"publicId":"2984060","version":"1","preferredName":"With Therapy Leukemia","longName":"2984060","preferredDefinition":"Used to indicate the presence of something or someone.: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.: A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood.  Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present.  Leukemia is usually associated with anemia, fever, hemorrhagic episodes and splenomegaly.  Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia.  Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"With","conceptCode":"C62355","definition":"Used to indicate the presence of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-7100-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7CE5ED33-7119-0231-E040-BB89AD435A9D","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"ONEDATA","dateModified":"2010-01-11","deletedIndicator":"No"},{"value":"Stable cytopenia, no cytogenetic abnormalities (no MDS)","valueDescription":"Stable Without Cytogenetic Abnormality Cytopenia","ValueMeaning":{"publicId":"2984057","version":"1","preferredName":"Stable Without Cytogenetic Abnormality Cytopenia","longName":"2984057","preferredDefinition":"Stable; subject to little fluctuation; showing little if any change.: Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.: A reduction in the number of blood cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable","conceptCode":"C30103","definition":"Subject to little fluctuation; showing little if any change.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytopenia","conceptCode":"C2979","definition":"A laboratory test result indicating an abnormally low quantity of circulating blood cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-7078-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B2045A13-860D-ADB5-E040-BB89AD4374D9","beginDate":"2010-01-11","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-11-18","modifiedBy":"ONEDATA","dateModified":"2011-11-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3336631","version":"1","preferredName":"Fanconi Anemia Status Type","preferredDefinition":"A rare and often fatal inherited disease in which the bone marrow fails to produce red blood cells, white blood cells, platelets, or a combination of these cells. The disease may transform into myelodysplastic syndrome or leukemia.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C62505:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B48D8287-C41D-B237-E040-BB89AD4318B5","latestVersionIndicator":"Yes","beginDate":"2011-12-20","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-12-20","modifiedBy":"ONEDATA","dateModified":"2011-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-7035-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"KUMMEROA","dateModified":"2021-03-15","changeDescription":". 2021-3-15 ak OK to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"fan_base_dx_status_prep","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the disease status o","type":"Preferred Question Text","description":"What was the disease status of the Fanconi Anemia?","url":null,"context":"NHLBI"},{"name":"What was the recipient's disease status immediately prior to the preparative regimen?","type":"Alternate Question Text","description":"What was the recipient's disease status immediately prior to the preparative regimen?","url":null,"context":"NHLBI"},{"name":"What was the disease status?","type":"Alternate Question Text","description":"What was the disease status?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE5ED33-712A-0231-E040-BB89AD435A9D","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"DWARZEL","dateModified":"2022-05-24","changeDescription":". 2021-3-15 ak OK to release per WZ. 2021-3-3 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}